Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-4361504119fec5762723adfabb108410"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-4361504119fec5762723adfabb108410"/>
<resource>
<Composition>
<id value="composition-en-4361504119fec5762723adfabb108410"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-4361504119fec5762723adfabb108410"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-4361504119fec5762723adfabb108410</b></p><a name="composition-en-4361504119fec5762723adfabb108410"> </a><a name="hccomposition-en-4361504119fec5762723adfabb108410"> </a><a name="composition-en-4361504119fec5762723adfabb108410-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1035/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - obizur</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1035/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp4361504119fec5762723adfabb108410"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - obizur"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What OBIZUR is and what it is used for</li><li>What you need to know before you are given OBIZUR</li><li>How OBIZUR is given</li><li>Possible side effects</li><li>How OBIZUR is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What obizur is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What obizur is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>OBIZUR contains the active substance susoctocog alfa, antihaemophilic factor VIII, porcine sequence. Factor VIII is necessary for the blood to form clots and stop bleedings. In patients with acquired haemophilia, factor VIII is not working properly because the patient has developed antibodies to his own factor VIII which neutralize this blood clotting factor.</p><p>OBIZUR is used for the treatment of bleeding episodes in adults with acquired haemophilia (a bleeding disorder caused by lack of factor VIII activity due to antibody development). These antibodies have less neutralizing effect against OBIZUR than against human factor VIII.</p><p>OBIZUR restores this missing factor VIII activity and helps blood to form clots at the site of bleeding.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take obizur"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take obizur"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The medicine is for in-patient administration only. It requires clinical supervision of the bleeding status of the patient.</p><p>You must not be given OBIZUR:</p><ul><li>if you are allergic to susoctocog alfa or any of the other ingredients of this medicine (listed in section 6);</li><li>if you are allergic to hamster proteins (trace amounts may be present in OBIZUR arising from the manufacturing process);</li><li>if you have congenital haemophilia A with inhibitors (CHAWI).</li></ul><p>If you are not sure, talk to your doctor before you are given this medicine.</p><p>Warnings and precautions Talk to your doctor before you are given OBIZUR. Hypersensitivity There is a rare chance that you may experience an allergic reaction to OBIZUR. You should be aware of the early signs of allergic reactions (see section 4 for signs and symptoms). If any of these symptoms occur, the injection should be stopped. Severe symptoms, including difficulty in breathing and (near) fainting, require emergency treatment in the hospital.</p><p>Inhibitors Your doctor may check if you have inhibitory antibodies to porcine factor VIII and for increases in these antibodies. Your doctor will check your blood factor VIII to confirm that enough factor VIII is being given to you. Your doctor will also check if the bleeding is adequately controlled.</p><p>Cardiovascular events Talk to your doctor if you currently have, or have had cardiovascular disease in the past or if you have a known risk of thrombosis (diseases from blood clots in normal vasculature), because the possiblity of developing thromboembolic diseases at high and sustained blood factor VIII levels cannot be excluded.</p><p>Children and adolescents There is no information on the use of OBIZUR in children and adolescents aged under 18 years</p><p>Other medicines and OBIZUR Tell your doctor if you are using, have recently used or might use any other medicines. No interactions of OBIZUR with other medicines are known.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>Driving and using machines OBIZUR has no influence on your ability to drive and use machines.</p><p>OBIZUR contains sodium This medicine contains 4.6 mg sodium (main component of cooking/table salt) per milliliter once it is made up. This is equivalent to 0.23% of the recommended maximum daily dietary intake of sodium for an adult. Multiple vials must be taken per dose.</p><p>Talk to your doctor if you are on a controlled sodium diet.</p></div>
</text>
</section>
<section>
<title value="3. How to take obizur"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take obizur"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Treatment with OBIZUR will be conducted by a doctor who is experienced in the care of patients with haemophilia (bleeding disorders).</p><p>Your doctor will calculate your dose of OBIZUR (in units or U) depending on your condition and body weight. The frequency and duration of administration will depend on how well OBIZUR is working for you. Usually, the replacement therapy with OBIZUR is a temporary treatment until bleeding is resolved or the antibodies against your own factor VIII are eradicated.</p><p>Your doctor will monitor you for antibodies to OBIZUR.</p><p>The recommended first dose is 200 U per kilogram bodyweight given by intravenous injection.</p><p>Your doctor will measure your factor VIII activity regularly to decide the subsequent dose and frequency of OBIZUR. The bleeding will usually respond within the first 24 hours, your doctor will adjust the dose and duration of OBIZUR until the bleeding stops. The total volume of reconstituted OBIZUR should be administered at a rate of 1 to 2 mL per minute.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If severe and sudden allergic reactions occur, the injection must be stopped immediately. You must contact your doctor immediately if you have any of the following early symptoms:</p><ul><li>Swelling of lips and tongue;</li><li>Burning and stinging at the injection site;</li><li>Chills, flushing;</li><li>Hives, generalised itching;</li><li>Headache, low blood pressure;</li><li>Lethargy, sickness, restlessness;</li><li>Rapid beating of the heart, tightness of the chest;</li><li>Tingling, vomiting;</li><li>Wheezing.</li></ul><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>Development of antibodies and increases in pre-existing antibodies against the medicine, which may result in lack of efficacy with continued bleeding.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store obizur"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store obizur"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton, on the vial and on the pre-filled syringe after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C 8 C). Do not freeze.</p><p>Use the reconstituted solution immediately but no longer than 3 hours once the powder is completely dissolved.</p><p>After reconstitution the solution should be clear and colourless. Do not administer if particulate matter or discolouration is found.</p><p>Since this medicine is used during hospitalisation, the hospital staff are responsible for the correct storage of this medicine before and during its use, as well as for correct disposal.</p><p>Name and batch number It is strongly recommended that every time that OBIZUR is used, the name and batch number of the medicine are recorded by the medical professional to maintain a link between your treatment and the batch of the medicine.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What OBIZUR contains</p><ul><li>The active substance is susoctocog alfa (antihaemophilic factor VIII, porcine sequence produced by recombinant DNA technology). Each powder vial contains 500 U of susoctocog alfa.</li><li>The other ingredients in the powder are polysorbate 80, sodium chloride (see also section 2), calcium chloride dihydrate, sucrose, trometamol, trometamol hydrochloride, sodium citrate.</li><li>The solvent is 1 ml sterilised water for injections.</li></ul><p>What OBIZUR looks like and contents of the pack One pack contains 1, 5 or 10 of the following:</p><ul><li>glass vial of OBIZUR 500 U white, friable powder with a butyl rubber stopper coated with FluroTec and a flip-off seal;</li><li>pre-filled glass syringe with a stopper of bromobutyl rubber coated with FluroTec foil on the contact side of 1 ml sterilised water for injections with a bromobutyl rubber tip cap and a Luer lock adapter;</li><li>fluid transfer device with an integral plastic spike.</li></ul><p>Marketing Authorisation Holder Baxalta Innovations GmbH Industriestrasse 1221 Vienna Austria</p><p>Manufacturer Takeda Manufacturing Austria AG Industriestrasse 1221 Vienna Austria</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Takeda Belgium NV T l/Tel: +32 2 464 06 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Lietuva Takeda, UAB Tel: +370 521 09 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>.: +359 2 958 27 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Luxembourg/Luxemburg Takeda Belgium NV T l/Tel: +32 2 464 06 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>esk republika Takeda Pharmaceuticals Czech Republic s.r.o. Tel: +420 234 722 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Magyarorsz g Takeda Pharma Kft. Tel.: +36 1 270 <a href="mailto:7medinfoEMEA@takeda.com">7medinfoEMEA@takeda.com</a></p><p>Danmark Takeda Pharma A/S Tlf: +45 46 77 10 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Malta akeda HELLAS S.A. Tel: +30 210 <a href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a></p><p>Deutschland Takeda GmbH Tel: +49 (0)800 825 <a href="mailto:3medinfoEMEA@takeda.com">3medinfoEMEA@takeda.com</a></p><p>Nederland Takeda Nederland B.V. Tel: +31 20 203 <a href="mailto:5medinfoEMEA@takeda.com">5medinfoEMEA@takeda.com</a></p><p>Eesti Takeda Pharma AS Tel: +372 6177 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Norge Takeda AS Tlf: +47 800 800 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>akeda . . T : +30 210 <a href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a></p><p>sterreich Takeda Pharma Ges.m.b.H.<br/>Tel: +43 (0) 800-20 80 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Espa a Takeda Farmac utica Espa a, S.A. Tel: +34 917 90 42 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Polska Takeda Pharma Sp. z o.o. Tel.: <a href="mailto:+48223062medinfoEMEA@takeda.com">+48223062medinfoEMEA@takeda.com</a></p><p>France Takeda France SAS T l: + 33 1 40 67 33 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Portugal Takeda Farmac uticos Portugal, Lda. Tel: + 351 21 120 <a href="mailto:1medinfoEMEA@takeda.com">1medinfoEMEA@takeda.com</a></p><p>Hrvatska Takeda Pharmaceuticals Croatia d.o.o. Tel: +385 1 377 88 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Rom nia Takeda Pharmaceuticals SRL Tel: +40 21 335 03 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Ireland Takeda Products Ireland Ltd Tel: 1800 937 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Slovenija Takeda Pharmaceuticals farmacevtska dru ba d.o.o. Tel: + 386 (0) 59 082 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>sland Vistor hf. S mi: +354 535 <a href="mailto:7medinfoEMEA@takeda.com">7medinfoEMEA@takeda.com</a></p><p>Slovensk republika Takeda Pharmaceuticals Slovakia s.r.o. Tel: +421 (2) 20 602 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Italia Takeda Italia S.p.A. Tel: +39 06 <a href="mailto:502medinfoEMEA@takeda.com">502medinfoEMEA@takeda.com</a></p><p>Suomi/Finland Takeda Oy Puh/Tel: 0800 774 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>akeda . . : +30 210 <a href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a></p><p>Sverige Takeda Pharma AB Tel: 020 795 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>Latvija Takeda Latvia SIA Tel: +371 <a href="mailto:67840medinfoEMEA@takeda.com">67840medinfoEMEA@takeda.com</a></p><p>United Kingdom (Northern Ireland) Takeda UK Ltd Tel: +44 (0) 2830 640 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p><p>This leaflet was last revised in .</p><p>This medicine has been authorised under exceptional circumstances . This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp4361504119fec5762723adfabb108410"/>
<resource>
<MedicinalProductDefinition>
<id value="mp4361504119fec5762723adfabb108410"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp4361504119fec5762723adfabb108410"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp4361504119fec5762723adfabb108410</b></p><a name="mp4361504119fec5762723adfabb108410"> </a><a name="hcmp4361504119fec5762723adfabb108410"> </a><a name="mp4361504119fec5762723adfabb108410-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1035/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: OBIZUR 500 U powder and solvent for solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1035/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="OBIZUR 500 U powder and solvent for solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
